The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10907 malaria professionals are enjoying the free benefits of MalariaWorld today


NOT Open Access | Monocyte Locomotion Inhibitory Factor confers neuroprotection and prevents the development of murine cerebral malaria

June 1, 2021 - 12:17 -- NOT Open Access
Galán-Salinas A, Corral-Ruíz G, Sánchez-Torres LE, et al.
Int Immunopharmacol. 2021 May 25;97:107674.

Cerebral malaria (CM) is a neurological complication derived from the Plasmodium falciparum infection in humans. The mechanisms involved in the disease progression are still not fully understood, but both the sequestration of infected red blood cells (iRBC) and leukocytes and an exacerbated host inflammatory immune response are significant factors. In this study, we investigated the effect of Monocyte Locomotion Inhibitory Factor (MLIF), an anti-inflammatory peptide, in a well-characterized murine model of CM. Our data showed that the administration of MLIF increased the survival and avoided the neurological signs of CM in Plasmodium berghei ANKA (PbA) infected C57BL/6 mice.

NOT Open Access | Identification of Plasmodium falciparum-specific protein PIESP2 as a novel virulence factor related to cerebral malaria

May 5, 2021 - 11:20 -- NOT Open Access
Liu X, Wu Y, Zhao Y, Huang Y, Xu K, Wang J, Pan S, Liang J
Int J Biol Macromol. 2021 Apr 30;177:535-547

Cerebral malaria (CM) is the most severe complication caused by Plasmodium falciparum infection. The pathophysiological changes caused by parasite virulence factors and the human immune response to parasites contribute to CM. To date, very few parasite virulence proteins have been found to participate in CM. Here, we employed comparative genomics analysis and identified parasite-infected erythrocyte specific protein 2 (PIESP2) to be a CM-related protein. We conducted further experimental investigations and found that PIESP2 is an immunogenic protein.

Subscribe to RSS - IRBC